ArticleGeoHealth2021
Tracking and Controlling the Spatiotemporal Spread of SARS-CoV-2 Lineage B.1.1.7 in COVID-19 Reopenings.
Article in GeoHealth, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Predicting onset risk of COVID-19 symptom to support healthy travel route planning in the new normal of long-term coexistence with SARS-CoV-2.Environment and planning. B, urban analytics and city science · 2023Article
- A Spatiotemporal Solution to Control COVID-19 Transmission at the Community Scale for Returning to Normalcy: COVID-19 Symptom Onset Risk Spatiotemporal Analysis.JMIR public health and surveillance · 2023Article
- Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127.Frontiers in public health · 2022Article
- How to control the spatiotemporal spread of Omicron in the region with low vaccination rates.Frontiers in public health · 2022Article
- Tracking and Controlling the Spatiotemporal Spread of SARS-CoV-2 Lineage B.1.1.7 in COVID-19 Reopenings.GeoHealth · 2021Article
- Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa.Travel medicine and infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding why or how the emergence of SARS-CoV-2 variants has occurred and how to control them is crucial as regards the potential of global reopening. To explore and further understand the spatiotemporal dynamics of the B.1.1.7 spread in the 368 districts of Taiwan, a district-level geographic prediction model of the risk of COVID-19 symptom onset has been proposed. It has been found that, (a) the human mobility, epidemic alert measures, and vaccination rates all played an important role in the spatiotemporal heterogeneity of B.1.1.7 transmission; (b) for regions with high human mobility and low vaccination rates, the partial relaxation of entry quarantine measures for specific imported groups would, in fact, lead to a wide spread of B.1.1.7 with a consequent doubling of high-onset-risk areas and together with the overall onset risk, a further increase of more than 20% would occur; (c) compared with the closing of business places and public venues in all districts, both lockdown in those areas of high-onset-risk and the gathered control effects regarding other districts, the control of B.1.1.7 spread would be better enabled by an onset risk reduction of up to 91.36%. Additionally, an increase in the vaccination rate in each district by up to 5-10 times would further reduce the onset risk by 6.07%-62.22%.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.